AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 251: E674-E679, 1986;
0193-1849/86 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, M. S.
Right arrow Articles by Reaven, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, M. S.
Right arrow Articles by Reaven, G. M.

AJP - Endocrinology and Metabolism, Vol 251, Issue 6 674-E679, Copyright © 1986 by American Physiological Society


ARTICLES

Somatostatin potentiation of insulin-induced glucose uptake in normal individuals

M. S. Wu, L. T. Ho, J. J. Chen, Y. D. Chen and G. M. Reaven

The ability of somatostatin (SRIF) to enhance insulin-stimulated glucose uptake was evaluated during clamp studies in normal individuals and patients with non-insulin-dependent diabetes mellitus (NIDDM). The results demonstrated that glucose uptake at insulin levels of approximately 100 microU/ml was significantly greater (P less than 0.001) in normal individuals in response to insulin plus SRIF as compared with insulin alone. In contrast, SRIF did not enhance insulin-stimulated glucose uptake in patients with NIDDM. Measurements were also made of the relative ability of insulin as compared with insulin plus SRIF to suppress C-peptide and glucagon concentrations during the clamp studies. The results of these experiments showed that SRIF did not potentiate the ability of insulin to suppress C-peptide concentrations in normal subjects but did in patients with NIDDM. However, plasma glucagon levels were reduced to a greater degree when SRIF was added to insulin in both normal and diabetic individuals.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online